Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and Vietnam

NCT03355664 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT03355664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03355664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and Vietnam
Lead sponsor
University of Oxford
Phase
Phase 3
Overall status
Completed
Start date
March 19, 2018
Completion date
March 4, 2020
Enrollment
310 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, falciparum